Zealand Pharma posts smaller-than-expected Q1 loss as obesity drugs advance
07/05/2026 06:05
May 7 (Reuters) - Danish drug developer Zealand Pharma ZELA.CO reported a smaller-than-expected first-quarter operating loss on Thursday, boosted by strong momentum in its obesity drug pipeline, and said it would launch a share buyback of up to $200 million. (Reporting by Jesus Calero and Vera Dvorakova) ((jesus.calero@thomsonreuters.com))
Recent news on Roche Holding AG
See all newsTable: Swiss trade surplus at CHF 6.11 bln in May
Brief: Roche - FDA Accepts Supplemental Biologics License Application For Lunsumio And Polivy Combination
Swiss stocks - Factors to watch on June 18
FDA approves first generic version of Roche's flu drug
Brief: FDA Approves First Single-Dose Generic Treatment For Influenza